Inc.®, a global leader in nanotechnology, is pleased to announce the
launch of its first completely configured protein array kit from its Nano BioDiscovery™
Division. Based on the patented Dip Pen Nanolithography® (DPN®) platform,
NanoInk's fluorescent assays enable nanoscale detection of clinically relevant
proteins. The inaugural Human Inflammation Cytokine Assay pairs the power of
DPN®-deposited protein arrays with a user-friendly protocol that can be
conducted on the lab bench without any special instrumentation. DPN provides
a biologically friendly nanoscale method of fabricating arrays without splashing,
which can lead to increased background noise, and without subjecting molecules
to sheer forces which may disrupt biological function. Additional assays being
developed for launch this year will target proteins implicated in various disease
states and toxicological responses.
Bruce Dudzik, NanoInk's Senior Director for Business Development, explained
that the Human Inflammation Cytokine Assay is a miniaturized immunoassay capable
of simultaneously evaluating multiple biomarkers in a single sub-array. This
multiplex assay measures a panel of 10 cytokines: IL-1alpha, IL-1beta, IL-2,
IL-3, IL-4, IL-5, IL-6, IL-8, IFNgamma and TNFalpha, plus a positive and a negative
control. The Human Inflammation Cytokine Assay kit includes nanoarrays of analyte-specific
antibodies and controls deposited on 1" x 3" modified glass slides.
Each slide is composed of 18 sub-arrays, with 48 features per sub-array. Twelve
different features (each printed in quadruplicate) are represented within each
48-feature sub-array. Feature size is less than 5µ. The Human Inflammation
Cytokine Assay kit also contains all reagents, buffers, standards, and slide
holders necessary to perform the assay and a detailed, validated user guide.
Result detection is accomplished offline using existing high-resolution fluorescent
scanners or microscopes.
"The Human Inflammation Cytokine Assay will achieve sensitivity as low
as the femtogram/ml range. Because DPN technology is capable of depositing highly
reproducible, submicron protein features in each sub-array, this assay can deliver
unmatched assay sensitivity even with the smallest of sample sizes. Just as
importantly, the Human Inflammation Cytokine Assay empowers multi-parallel,
high throughput analysis. NanoInk will continue to lead the way in multiplex
protein studies, with our line of assay kits and contract research services,"
The Nano BioDiscovery Division provides a new generation of array-based instrument
systems, assay kits, and contract services for nanoscale protein detection.
By combing DPN nanofabrication technology with optimized substrates and next-generation
detection systems for a total system solution, Nano BioDiscovery helps its customers
address major proteomic challenges.